Cancer News and Research

Latest Cancer News and Research

Birmingham dermatologist first to offer anti-cellulite Cellulaze procedure

Dr. Barry Ginsburg, a Birmingham, AL based Dermatologist today announced his practice is the first in the state to offer the Cellulaze by Cynosure, the world's first and only minimally invasive medical device designed to treat women who have struggled to eliminate cellulite through diet and exercise, or have tried the myriad of lotions and creams currently on the market.

20 Feb 2012

James E. Cary Cancer Center to implement RayStation treatment planning system

RaySearch Laboratories AB has received an order for its RayStation treatment planning system from the James E. Cary Cancer Center located in Hannibal, Missouri.

20 Feb 2012

Charité launches new EU research project to personalize breast cancer treatment

Adjusting breast cancer therapy to individual patients to avoid ineffective treatment: Charité Universitätsmedizin Berlin and eleven partner institutions from six countries have set this as their goal. They have launched the EU research project RESPONSIFY.

20 Feb 2012

KI's chemical interaction map shows how inhibitors bind to PARP enzymes

A team of researchers at Karolinska Institutet in Sweden has generated a map over the effects of small drug-like molecules on PARP1 and other similar proteins in the body. This map may explain the mechanism behind putative side effects of the so-called PARP inhibitors, and can play an important role in the development of novel tailor-made cancer drugs.

20 Feb 2012

ASI receives FDA clearance for GenASIs Scan and Analysis

Applied Spectral Imaging (ASI) announces that ASI's GenASIs automated scanning and image analysis system for detection and quantifying chromosome 17 and the HER-2/neu gene has been cleared by the United States Food and Drug Administration (FDA) for marketing in the US.

20 Feb 2012

DNA ‘nanorobot’ effectively targets cancer leaving healthy cells untouched: Study

Researchers have developed ‘nano-sized’ probes built from DNA that can seek and destroy cancer cells, leaving healthy cells untouched. These ‘nanorobots’ release their drug payload only when they reach and identify their target and are believed to improve many treatments for disease.

20 Feb 2012

EC approves Plexxikon's Zelboraf to treat BRAF mutation-positive MM

Plexxikon Inc., a member of Daiichi Sankyo Group, today announced that the European Commission has approved Zelboraf (vemurafenib) for the monotherapy treatment of adult patients with BRAFV600 mutation-positive unresectable or metastatic melanoma.

20 Feb 2012

Indiana CTSI HUB offers open-source software to accelerate clinical and translational research

At a time when medical research increasingly requires collaboration by large numbers of busy people, the Indiana Clinical and Translational Science Institute HUB offers a model for using advanced information technology to link scientists, health providers, community partners and others for the purpose of accelerating clinical and translational research.

20 Feb 2012

Substituting smokeless tobacco products can save smokers' lives

Substituting smokeless tobacco products can save smokers' lives, and there is a scientific foundation that proves it.

20 Feb 2012

Study identifies USP15 as a critical protein in cancer

After years studying the molecular bases of glioblastoma - the most common brain tumor and one of the most aggressive of all cancers, the group led by Dr. Joan Seoane , Director of Translational Research at the Vall d'Hebron Institute of Oncology (VHIO) and ICREA Research Professor has today published a study in Nature Medicine identifying USP15 as a critical protein in cancer which, thanks to its molecular characteristics, shows enormous therapeutic promise.

20 Feb 2012

Modified imatinib cancer drug prevents morphine tolerance in rats

By reformulating the common cancer drug imatinib (Gleevec), researchers have eliminated morphine tolerance in rats - an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center.

20 Feb 2012

Defects in GPR120 protein may lead to obesity and liver disease

Defects in a protein that functions as a dietary fat sensor may be a cause of obesity and liver disease, according to a study published in the journal Nature, led by researchers at Imperial College London. The findings highlight a promising target for new drugs to treat obesity and metabolic disorders.

19 Feb 2012

Penn oncologist to discuss role of autophagy in fighting cancer at AAAS annual meeting

Blocking autophagy -- the process of "self-eating" within cells -- is turning out to be a viable way to enhance the effectiveness of a wide variety of cancer treatments.

19 Feb 2012

Evolution of cancer genome to be discussed at 2012 AAAS annual meeting

Professor Mike Stratton, Director of the Wellcome Trust Sanger Institute, will speak about 'the evolution of the cancer genome' at the prestigious 2012 American Association for the Advancement of Science annual meeting. The AAAS annual meeting is one of the world's most widely recognized science events.

19 Feb 2012

Bristol-Myers Squibb awards 3 new grants to enhance HBV and HCV prevention, diagnosis and care

The Bristol-Myers Squibb Foundation has awarded three new grants to improve prevention, diagnosis and care of hepatitis B (HBV) and hepatitis C (HCV) in China and India as part of its Delivering Hope: Awareness, Prevention and Care umbrella program which is committed to reducing hepatitis-related health disparities in Asia.

19 Feb 2012

Arsenic found in baby formula containing organic brown rice syrup

Rice is among the plants that are efficient in taking up arsenic from the soil, environmental chemist Brian Jackson of Dartmouth College in Hanover, N.H., and his co-authors said in Thursday's issue of the journal Environmental Health Perspectives. Long-term exposure to extremely high levels of inorganic arsenic can increase the risk of lung, liver and bladder cancer as well as miscarriage and infertility.

18 Feb 2012

OICR launches Phase III Active Surveillance Magnetic Resonance Imaging Study Trial

Dr. Nicole Onetto, Deputy Director and Chief Scientific Officer of the Ontario Institute for Cancer Research (OICR), today announced the launch of an innovative Phase III clinical trial that aims to determine whether multi-parametric magnetic resonance imaging (MRI) coupled with transrectal ultrasound (TRUS) guided biopsy (called fusion technology) can accurately identify men with prostate cancer who are at risk of developing aggressive disease.

18 Feb 2012

NPAF commends passage of bill for parity in insurance coverage for orally administered chemotherapy

Representatives of Virginia's patient advocacy community praised the State House of Representatives and State Senate today for voting strongly in support of legislation that, if enacted, will help thousands of Virginia's insured cancer patients who are currently unable to access their physician-prescribed chemotherapy treatment regimens of choice.

18 Feb 2012

FDA prioritizes review of Ra-223 and MDV3100 for treating CRPC

The arsenal of prostate cancer treatments for men with advanced prostate cancer may soon be strengthened as the FDA prioritizes the review of both Ra-223 and MDV3100 for treating metastatic castration-resistant prostate cancer (CRPC). Based on positive, independent research of each drug, better survival rates and improved bone health for patients with late-stage prostate cancer may be within reach.

18 Feb 2012

Elekta's Fraxion integrates all proven cranial immobilization options in a single solution

The Fraxion head frame helps ensure accuracy and precision in stereotactic radiation therapy (SRT) of cancer targets in the brain and cranium. Elekta's Fraxion is the first to introduce an innovative system that integrates all proven cranial immobilization options in a single solution.

From Elekta 18 Feb 2012